3D bioprinting of vascular conduits for pediatric congenital heart repairs

Wenhan Lee1, Yi Hong2, Guohao Dai1

  • 1Department of Bioengineering, Northeastern University, Boston, Massachusetts.

Insights

Tissue engineered vascular grafts (TEVGs) are crucial for pediatric congenital heart defect repair. Current research focuses on 3D bioprinting for patient-specific grafts, aiming for improved long-term performance.

Area of Science:

  • Biomedical Engineering
  • Pediatric Cardiology
  • Regenerative Medicine

Background:

  • Congenital heart defects in children necessitate surgical correction using grafts, patches, or conduits.
  • Pediatric cardiovascular anatomy varies, requiring tailored surgical approaches and precisely designed grafts sensitive to hemodynamic environments.
  • Tissue engineered vascular grafts (TEVGs) show promise but fabricating patient- and operation-specific grafts remains challenging.

Purpose of the Study:

  • To review historical milestones and clinical outcomes of TEVG development for pediatric congenital defect repair.
  • To highlight advancements in 3D bioprinting of TEVGs with complex geometries.
  • To address current limitations in TEVG fabrication and future research directions.

Main Methods:

  • Review of historical development and clinical outcomes of TEVGs in pediatric surgery.
  • Analysis of current research on 3D bioprinting techniques for TEVG fabrication.
  • Discussion of challenges and limitations associated with TEVG technologies.

Main Results:

  • Significant progress has been made in TEVG development over the past decade.
  • 3D bioprinting offers potential for creating TEVGs with complex, patient-specific geometries.
  • Current 3D bioprinted vascular grafts lack appropriate functions, but research is promising.

Conclusions:

  • Developing functional, patient-specific TEVGs for pediatric congenital heart defect repair is an ongoing challenge.
  • 3D bioprinting represents a promising avenue for future TEVG innovation.
  • Continued research is essential to overcome limitations and achieve successful clinical application of TEVGs.

Related Concept Videos

Mismatch Repair01:36

Mismatch Repair

Overview
43.6K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.4K
Overview of DNA Repair02:25

Overview of DNA Repair

In order to be passed through generations, genomic DNA must be undamaged and error-free. However, every day, DNA in a cell undergoes several thousand to a million damaging events by natural causes and external factors. Ionizing radiation such as UV rays, free radicals produced during cellular respiration, and hydrolytic damage from metabolic reactions can alter the structure of DNA. Damages caused include single-base alteration, base dimerization, chain breaks, and cross-linkage.
Chemically...
33.5K
Base Excision Repair01:54

Base Excision Repair

One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...
26.2K
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

Overview
40.6K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.9K